LLY

1,042.36

-1.13%↓

JNJ

210.54

+0.48%↑

ABBV

224.13

+0.08%↑

UNH

331.16

-0.89%↓

AZN

89.91

-1.6%↓

LLY

1,042.36

-1.13%↓

JNJ

210.54

+0.48%↑

ABBV

224.13

+0.08%↑

UNH

331.16

-0.89%↓

AZN

89.91

-1.6%↓

LLY

1,042.36

-1.13%↓

JNJ

210.54

+0.48%↑

ABBV

224.13

+0.08%↑

UNH

331.16

-0.89%↓

AZN

89.91

-1.6%↓

LLY

1,042.36

-1.13%↓

JNJ

210.54

+0.48%↑

ABBV

224.13

+0.08%↑

UNH

331.16

-0.89%↓

AZN

89.91

-1.6%↓

LLY

1,042.36

-1.13%↓

JNJ

210.54

+0.48%↑

ABBV

224.13

+0.08%↑

UNH

331.16

-0.89%↓

AZN

89.91

-1.6%↓

Inicio・Lista de Acciones・Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Cerrado

SectorSanidad

23.97 -0.99

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

23.81

Máximo

24.44

Métricas clave
By Trading Economics
Ingresos	675K 53M
Ventas	1.8M 148M
P/B Media del Sector	14.14 76.798
Margen de beneficios	35.57
Empleados	181
EBITDA	1.7M 80M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+40.55% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	348M 3B
Apertura anterior	24.96
Cierre anterior	23.97

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

N/A / 24.28 Soporte y Resistencia

Catalyst Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

17 dic 2025, 23:50 UTC

Acciones populares

Stocks to Watch: Micron, MillerKnoll, HireQuest, Insmed

17 dic 2025, 23:20 UTC

Ganancias

Correction to Micron Logs Sales Jump Article

17 dic 2025, 23:07 UTC

Ganancias

Micron Logs Sales Jump, Sees Further Growth as AI Demand Outpaces Supply -- Update

17 dic 2025, 21:37 UTC

Ganancias

Micron Technology 1Q Sales Jump 57%, Led By Memory Growth

17 dic 2025, 23:53 UTC

Charlas de Mercado

Gold Edges Higher, Supported by Some Tailwinds -- Market Talk

17 dic 2025, 23:43 UTC

Charlas de Mercado

Nikkei May Fall, Tracking Wall Street's Decline -- Market Talk

17 dic 2025, 23:06 UTC

Adquisiciones, fusiones, absorciones

Asahi Group: Transaction Expected to Be Closed in 2H of Calendar Year 2026

17 dic 2025, 23:05 UTC

Adquisiciones, fusiones, absorciones

Asahi Group: Currently No Plans of Issuing New Shares in Asahi

17 dic 2025, 23:04 UTC

Adquisiciones, fusiones, absorciones

Asahi Group: Funds to Be Provided Via Borrowings From Financial Institutions or Cash on Hand

17 dic 2025, 23:03 UTC

Adquisiciones, fusiones, absorciones

Asahi Group: Acquisition of 53.68% Stake in UDV (Kenya) is $646M on Equity Value Basis

17 dic 2025, 23:02 UTC

Adquisiciones, fusiones, absorciones

Asahi Group: Acquisition of 100% Stake in Diageo Kenya is $2.354B on Equity Value Basis

17 dic 2025, 22:59 UTC

Adquisiciones, fusiones, absorciones

Asahi Group: Deal Part of Strategy Under Medium- to Long-Term Management Policy

17 dic 2025, 22:57 UTC

Adquisiciones, fusiones, absorciones

Asahi Group: To Indirectly Acquire 65.00% Stake in East African Breweries PLC

17 dic 2025, 22:56 UTC

Adquisiciones, fusiones, absorciones

Asahi Group: Stakes Acquired From Two Subsidiaries of Diageo Plc

17 dic 2025, 22:55 UTC

Adquisiciones, fusiones, absorciones

Asahi Group Holdings: To Acquire 100% Stake in Diageo Kenya Ltd., 53.68% Stake in UVD (Kenya) Ltd.

17 dic 2025, 22:49 UTC

Charlas de Mercado

Sandfire Resources Production Pipeline Strength Questioned -- Market Talk

17 dic 2025, 21:58 UTC

Ganancias

Micron Crushes Earnings. The Stock Is Rising. -- Barrons.com

17 dic 2025, 21:50 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Tech, Media & Telecom Roundup: Market Talk

17 dic 2025, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

17 dic 2025, 21:46 UTC

Ganancias

Salesforce and Other AI Stocks That Can Catch Up to the Pack -- Barrons.com

17 dic 2025, 21:20 UTC

Ganancias

Micron Crushes Earnings. The Stock Is Rising. -- Barrons.com

17 dic 2025, 21:10 UTC

Ganancias

Micron Beats Earnings. The Stock Is Rising. -- Barrons.com

17 dic 2025, 21:05 UTC

Ganancias

Micron Technology Anticipates Business Performance to Continue Strengthening Through FY26

17 dic 2025, 21:04 UTC

Ganancias

Micron Technology: 2Q Outlook Reflects Substantial Records Across Rev, Gross Margin, EPS and Free Cash Flow >MU

17 dic 2025, 21:04 UTC

Ganancias

Micron Technology Sees 2Q Oper Expenses $1.56B, Plus or Minus $20M >MU

17 dic 2025, 21:03 UTC

Ganancias

Micron Technology Sees 2Q Adj EPS $8.42, Plus or Minus 20c >MU

17 dic 2025, 21:03 UTC

Ganancias

Micron Technology Sees 2Q EPS $8.19, Plus or Minus 20c >MU

17 dic 2025, 21:03 UTC

Ganancias

Micron Technology Sees 2Q Revenue $18.7B, Plus or Minus $400M >MU

17 dic 2025, 21:02 UTC

Ganancias

Micron Technology 1Q Operating Cash Flow $8.41 B >MU

17 dic 2025, 21:01 UTC

Ganancias

Micron Technology 1Q Rev $13.64B >MU

Comparación entre iguales

Cambio de precio

Catalyst Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

40.55% repunte

Estimación a 12 Meses

Media 34 USD 40.55%

Máximo 35 USD

Mínimo 33 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Catalyst Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

5 ratings

Comprar

Mantener

Vender

De acuerdo con 5 analistas que ofrecen calificaciones bursátiles a para Catalyst Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

N/A / 24.28Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.